Dr Reddy's Laboratories today said it has acquired GlaxoSmithKline's US penicillin manufacturing facility and the rights to the Augmentin and Amoxil brands in the United States for an undisclosed sum.
"GSK will retain the existing rights of these brands outside the United States," Dr Reddy's said in a filing to the Bombay Stock Exchange (BSE).
The acquisition of the oral pencillin manufacturing facility in Bristol and product portfolio was completed yesterday and is pursuant to the agreement signed by the companies on November 23, 2010, it added.
The company, however, did not disclose the financial terms and conditions of the transaction.
Brands Augmentin and Amoxil, which are used for treating bacterial infections, are trademarks of GlaxoSmithKline.
Shares of Dr Reddy's were being quoted at Rs 1,628.50 apiece in afternoon trade on the BSE today, up 2.21% from their previous close.
